ADB-F Cannabinoid For Sale USA
ADB-F (ADB-FUBINACA) is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.
ADB-F– is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration. Coming under particular regulatory scrutiny, ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and SDB-005
ADB-FUBINACA is a designer drug found in synthetic cannabis blends in Japan. It features an amide group at the 3-indazole position, similar to SDB-001 and STS-135.
ADB-F is a designer drug with a carboxamide group attached to an indazole core. It was the third most commonly encountered synthetic cannabinoid in 2018.
ADB-FUBINACA is a new designer drug identified in Japan.
ADB-FUBINACA is a synthetic drug that mimics the effects of natural cannabinoids in the body.
A designer drug identified in synthetic cannabis blends in Japan since 2013, ADB-F has a carboxamide group at the 3-indazole position. It appears to be the product of rational drug design since it differs from AB-FUBINACA only by replacing the isopropyl group with a tert-butyl group.
N-(1-Adamantyl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (also known as ADB-FUBINACA) is a synthetic cannabinoid that has been identified in synthetic cannabis blends in Japan since 2013. It is the product of rational drug design due to the presence of a tert-butyl group at the 3-indazole position instead of the isopropyl group present in its close analog, AB-FUBINACA.
ADB-FUBINACA(ADB-F) is a synthetic cannabinoid that was first identified in Japan in 2013. It is the product of rational drug design since it is a minor modification of AB-FUBINACA that contains a tert-butyl group instead of an isopropyl group.
ADB-F is an indazole-based synthetic cannabinoid that acts as a potent agonist of the CB1 receptor and the CB2 receptor with EC values of 1 nM and 0.58 nM, respectively.
ADB-F is an indazole-based synthetic cannabinoid and designer drug discovered in 2013. It acts as an agonist for the cannabinoid receptors CB1 and CB2, with EC50 values of 1.2 nM for the CB1 receptor and 3.5 nM for the CB2 receptor. It features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.
ADB-F is a designer drug identified in synthetic cannabis blends in Japan in 2013. In 2018, it was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration.
ADB-F is a synthetic designer drug identified in synthetic cannabis blends in Japan in 2013. It was the third-most common synthetic cannabinoid identified in drugs seized by the Drug Enforcement Administration in 2018.
ADB-F is a designer drug identified as part of synthetic cannabis blends in Japan in 2013. In 2018, it was the 3rd most common synthetic cannabinoid identified by the Drug Enforcement Administration (DEA) in the United States.
ADB-F is a designer drug. It is a synthetic cannabinoid identified in Japan in 2013. In 2018, it was the third most common synthetic cannabinoid identified by the Drug Enforcement Administration.
ADB-F (MN-24, AKB48) is a cannabimimetic, a class of compounds that act similarly to classical cannabinoids like tetrahydrocannabinol.
ADB-F is a designer drug reported as a potent agonist of the CB1 receptor and the CB2 receptor.
Why Buy ADB-F Online From Us?
We are a long established and trusted supplier of Research Chemicals
Best RC Vendor online
Our RC are of high purity 99.9%
We provide shipping Tracking Number once parcel is shipped.
Our customers leave genuine reviews which allow you to buy with confidence
Everest Chemicals makes it possible for you to access the best quality research chemicals , Psychedelics, Cannabinoids ,Empathogens and more. We ship allover USA, UK, Europe, Australia, Canada and Asia .